MAIA Biotechnology, Inc. (MAIA) Research

MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.

Market snapshot

Symbol
MAIA
Price
$1.40
Day change
+6.06%
Market cap
$85.1M
P/E ratio
-1.85x
52-week range
0.87-3.19
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Annovis Bio, Inc. (ANVS)
  • BioAtla, Inc. (BCAB)
  • CalciMedica, Inc. (CALC)
  • Celularity Inc. (CELU)
  • Elutia Inc. (ELUT)
  • Lantern Pharma Inc. (LTRN)
  • PolyPid Ltd. (PYPD)
  • RenovoRx, Inc. (RNXT)

Recent insider activity

  • Vitoc Vlad — P-Purchase (72700 shares) on 2026-06-01
  • Smith Stan — P-Purchase (75000 shares) on 2026-06-01
  • Gryaznov Sergei — P-Purchase (2000 shares) on 2026-06-01
  • Vitoc Vlad — A-Award (800000 shares) on 2026-05-29
  • Gryaznov Sergei — A-Award (400000 shares) on 2026-05-29

Open MAIA Biotechnology, Inc. (MAIA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.